Eliem Therapeutics Inc (ELYM)
8.17
-0.01
(-0.12%)
USD |
NASDAQ |
May 17, 16:00
8.17
0.00 (0.00%)
After-Hours: 20:00
Eliem Therapeutics Cash from Investing (Quarterly): 13.75M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 13.75M |
December 31, 2023 | 36.75M |
September 30, 2023 | 28.04M |
June 30, 2023 | -1.601M |
March 31, 2023 | 5.797M |
December 31, 2022 | 14.28M |
September 30, 2022 | 8.509M |
June 30, 2022 | 15.69M |
Date | Value |
---|---|
March 31, 2022 | -4.035M |
December 31, 2021 | -8.051M |
September 30, 2021 | -106.92M |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 8.078M |
September 30, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-106.92M
Minimum
Sep 2021
36.75M
Maximum
Dec 2023
0.6853M
Average
5.797M
Median
Mar 2023
Cash from Investing (Quarterly) Benchmarks
Alpine Immune Sciences Inc | -2.562M |
Candel Therapeutics Inc | -0.007M |
Cyclacel Pharmaceuticals Inc | 0.00 |
Lipocine Inc | -4.090M |
GlycoMimetics Inc | -0.0074M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -1.819M |
Cash from Financing (Quarterly) | 0.015M |
Free Cash Flow | -7.241M |
Free Cash Flow Per Share (Quarterly) | -0.0658 |
Free Cash Flow Yield | -3.22% |